Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
19 NC counties are under alert, including Wayne, Moore, Sampson, and Hoke counties.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
6.810
-0.090 (-1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
December 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
November 20, 2023
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.
Via
Benzinga
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
November 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
November 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Why Aurinia Pharmaceuticals Stock Is Slumping Today
September 18, 2023
The biotech's premium valuation doesn't seem to be sitting well with investors.
Via
The Motley Fool
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
October 30, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation.
Via
Benzinga
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
May 18, 2023
Via
Benzinga
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
October 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
October 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
October 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
September 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
August 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
August 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
July 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
July 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
June 30, 2023
The biotech's board is exploring strategic alternatives to boost shareholder value.
Via
The Motley Fool
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
June 30, 2023
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say.
Via
Investor's Business Daily
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
June 30, 2023
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or
Via
Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
June 30, 2023
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 30, 2023
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today!
Via
InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
June 29, 2023
Via
Benzinga
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
June 29, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
June 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
June 01, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
May 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2023 Annual General Meeting Results
May 17, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.